PAS1

HEALTH CARE UTILIZATION, COST AND MEDICATION USE AMONG PEDIATRIC ASTHMA PATIENTS
Modi A, Iyer R, Lawrence L
University of Louisiana at Monroe, Monroe, LA, USA

PAS2

IMPACT OF ANTI-INFLAMMATORY MEDICATION ON ASTHMA COSTS IN A PEDIATRIC POPULATION
Sapra SJ¹, Martin BC², Dorfman JH^3
1 University of California, San Francisco, CA, USA; ² University of Arkansas for Medical Sciences, Little Rock, AR, USA; ³ University of Georgia, Athens, GA, USA

PAS3

A COMPARISON OF ASTHMA MEDICATION USE IN PUBLICLY VERSUS PRIVATELY INSURED CHILDREN WITH ASTHMA
Ungar WJ¹, Kozyrskyj A², Paterson M³, Mamdani M³, Gunraj N³, Ahmad F^4
1 The Hospital for Sick Children, Toronto, ON, Canada; ² Manitoba Centre for Health Policy, Winnipeg, MB, Canada; ³ Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; ⁴ Brogan Inc, Ottawa, ON, Canada

PAS4

PATTERNS OF PHARMACOTHERAPY UTILIZATION AMONG CHILDREN AND ADOLESCENTS WITH MULTIPLE ASTHMA-RELATED MORBID EVENTS ENROLLED IN A MEDICAID PROGRAM
D'Souza AO, Smith M, Roy AN
West Virginia University, Morgantown, WV, USA

PAS5

DRUG COST ANALYSIS OF TREATMENT FOR ASTHMA OUTPATIENTS IN TAIWAN
Lu CH¹, Tarn YH^2
1 National Defense Medical Center, Taipei, Taipei, Taiwan; ² Taipei City Hospital, Taipei, Taiwan

PAS6

IMPACT OF ASTHMA KNOWLEDGE ON HEALTH OUTCOMES IN PEDIATRIC PATIENTS
Suksomboon N, Montakantikul P
Mahidol University, Payathai, Bangkok, Thailand

PAS7

DIRECT AND INDIRECT COST OF ASTHMA IN AN EMPLOYER POPULATION
Atherly A, Nurmagambetov T, Williams S
Centers for Disease Control and Prevention, Atlanta, GA, USA

PAS8

A DYAD APPROACH TO QUALITY OF LIFE MEASUREMENT IN CHILDREN WITH ASTHMA
Mirabelli C, Cousins M, Boydell K, Ungar WJ
The Hospital for Sick Children, Toronto, ON, Canada

PAS9

CHOOSING AMONG DIFFERENT TYPES OF MATCHING TECHNIQUES
Baser O
Medstat, Inc, Ann Arbor, MI, USA

PCV1

COMPARISON OF ALTERNATIVE STRATEGIES FOR THE DIAGNOSIS OF ACUTE CARDIAC ISCHEMIA IN EMERGENCY DEPARTMENTS: STANDARD OF CARE VERSUS BMIPP
Wu EQ¹, Birnbaum H¹, Cremieux P¹, Carpenter S¹, Borys N², Babich JW², Setnik G^3
1 Analysis Group, Inc, Boston, MA, USA; ² Molecular Insight Pharmaceuticals, Cambridge, MA, USA; ³ Mt Auburn Hospital, Cambridge, MA, USA

PCV2

ACUTE CORONARY SYNDROMES: ONE YEAR COSTS AND OUTCOMES
Taylor M¹, Scuffham P², McCollam PL³, Newby D^4
1 York Health Economics Consortium, Heslington, York, United Kingdom; ² School of Population Health, Herston, Queensland, Australia; ³ Eli Lilly and Company, Indianapolis, IN, USA; ⁴ University of Edinburgh, Edinburgh, East Lothian, United Kingdom

PCV3

UTILIZATION OF RECOMMENDED DRUG THERAPY IN ACUTE CORONARY SYNDROME
Patel CK, McCollam PL, Bae JP
Eli Lilly and Company, Indianapolis, IN, USA

PCV4

LONG-TERM THIENOPYRIDINE THERAPY IN ACS PATIENTS RESIDING IN THE UNITED KINGDOM
McCollam PL¹, Lage MJ², Bowman L^1
1 Eli Lilly and Company, Indianapolis, IN, USA; ² HealthMetrics Outcomes Research, Groton, CT, USA

PCV5

POTENTIAL COST SAVINGS FROM ACUTE CORONARY SYNDROME TREATMENT IMPROVEMENTS
Klein RW¹, Ohsfeldt RL², Smolen LJ¹, McCollam PL^3
1 Medical Decision Modeling Inc, Indianapolis, IN, USA; ² The University of Iowa College of Public Health, Iowa City, IA, USA; ³ Eli Lilly and Company, Indianapolis, IN, USA

PCV6

LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDOGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (CREDO TRIAL): A FOUR-EUROPEAN COUNTRY ANALYSIS
Weintraub WS¹, Bouin O², Veledar E¹, Gabriel S^2
1 Emory University, Atlanta, GA, USA; ² Sanofi-Aventis, Bagneux, France

PCV7

HEALTH CARE RESOURCE UTILIZATION AND COST OF ATRIAL FLUTTER PATIENTS
Pelletier E¹, Reyes CM¹, Hernandez J¹, Lee BK^2
1 Boston Scientific Corporation, San Jose, CA, USA; ² University of California San Francisco, San Francisco, CA, USA

PCV8

TOTAL HEALTH CARE COSTS OF PATIENTS WITH CHRONIC NON-VALVULAR ATRIAL FIBRILLATION BEFORE AND AFTER TIA, ISCHEMIC STROKE OR MAJOR BLEED
Stephenson JJ¹, Fernandes J¹, Beaulieu JF¹, Del Aguila MA¹, Hauch O², Kim J², Boccuzzi SJ^1
1 Aetna Health Information Solutions, Blue Bell, PA, USA; ² AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PCV9

COST-EFFECTIVENESS OF AMIODARONE TO PREVENT ATRIAL FIBRILLATION AFTER CARDIAC SURGERY
Reddy P¹, Gao X², Burrell A³, Boci K², Bouin O^4
1 Abt Associates Inc, Lexington, MA, USA; ² Abt Associates Inc, Bethesda, MD, USA; ³ Sanofi-Aventis, Bridgewater, NJ, USA; ⁴ Sanofi-Aventis, Bagneux, France

PCV10

RACE AND GENDER COST DIFFERENCES ASSOCIATED WITH COMORBID ATRIAL FIBRILLATION IN THE HOSPITAL SETTING
Coyne KS¹, Paramore LC¹, Grandy S², Mercader M³, Reynolds M⁴, Zimetbaum PJ^4
1 MEDTAP International, Inc, Bethesda, MD, USA; ² AstraZeneca, LP, Wilmington, DE, USA; ³ George Washington University, Washington, DC, USA; ⁴ Beth Israel Deaconess Medical Center, Boston, MA, USA

PCV11

QUALITY OF ANTICOAGULATION CONTROL IN PATIENTS WITH ATRIAL FIBRILLATION MANAGED IN ROUTINE MEDICAL CARE IN THE UNITED STATES
Ansell JE¹, Caro JJ², Proskorovsky I³, Lordan N², Salas M², Hauch O⁴, Wygant G⁴, Hollowell J⁵, Bjorholt I^6
1 Boston Medical - Boston University, Boston, MA, USA; ² Caro Research, Concord, MA, USA; ³ Caro Research Institute, Dorval, QC, Canada; ⁴ AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA; ⁵ AstraZeneca R&D Mölndal, Mölndal, Sweden; ⁶ Nordic Health Economics Research AB, Hovas, Sweden

PCV12

DATA CAPTURE VIA INTERACTIVE VOICE RESPONSE SYSTEM IN A NATIONAL STUDY OF ANTICOAGULATION MANAGEMENT
Payne K¹, Lordan N², Caro JJ², O'Brien J^2
1 Caro Research Institute, Dorval, QC, Canada; ² Caro Research Institute, Concord, MA, USA

PCV13

COST-EFFECTIVENESS EVALUATION OF EPLERENONE IN PATIENTS WITH HEART FAILURE FOLLOWING AMI IN GERMANY
Kvasz M¹, Zhang Z², Lenz C³, Mundhenke M³, Weintraub WS^2
1 Pfizer Inc, New York, NY, USA; ² Emory University, Atlanta, GA, USA; ³ Pfizer Pharma GmbH, Karlsruhe, Germany

PCV14

MODELING THE ECONOMIC CONSEQUENCES OF CARDIAC RESYNCHRONIZATION THERAPY IN THE UK
Caro JJ, Drummond TL
Caro Research, Concord, MA, USA

PCV15

POTENTIAL MEDICAL COST OFFSETS OF TREATMENT WITH ISOSRBIDE DINITRATE PLUS HYDRALAZINE IN AFRICAN AMERICANS WITH HEART FAILURE
Becker R¹, Klingman D^2
1 ValueMedics Research, Chicago, IL, USA; ² ValueMedics, Falls Church, VA, USA

PCV16

INCREMENTAL EFFECTS OF CONCURRENT PHARMACOTHERAPEUTIC REGIMENS FOR HEART FAILURE ON HOSPITALIZATIONS AND COSTS
Skrepnek GH¹, Abarca J¹, Malone DC¹, Armstrong EP¹, Shirazi FM², Woosley RL^2
1 University of Arizona College of Pharmacy, Tucson, AZ, USA; ² University of Arizona College of Medicine, Tucson, AZ, USA

PCV17

CAREMARK CAREPATTERNS®HEART FAILURE HOME MONITORING PROGRAM IMPROVES PARTICIPANTS’ HOME MONITORING COMPLIANCE
Fensterheim LE¹, Duff D², Sellers Y², Hu L¹, Stine N^1
1 Caremark Inc, Northbrook, IL, USA; ² Caremark Inc, San Antonio, TX, USA

PCV18

USE OF ß-BLOCKERS FOR TREATING HEART FAILURE AMONG THE ELDERLY IN BRITISH COLUMBIA, CANADA, 1993-2001
Levy A¹, Johnston K¹, Gustafson P¹, Palepu A¹, Reid R², Brophy J³, Mcgrail K^1
1 University of British Columbia, Vancouver, BC, Canada; ² Group Health Permanente, Seattle, WA, USA; ³ McGill University, Montreal, QC, Canada

PCV19

TRENDS IN PHARMACY USE AMONG VETERANS WITH CHRONIC HEART FAILURE (1999-2002)
Johnson ML, Henderson L, Petersen N, Espadas D, Yu H, Campbell J, Moffett M, Deswal A
Baylor College of Medicine, Houston, TX, USA

PCV20

DECREASING HOSPITALIZATIONS FOR HEART FAILURE IN BRITISH COLUMBIA, CANADA, 1993-2001
Levy A¹, Johnston K¹, Gustafson P¹, Palepu A¹, Reid R², Brophy J³, Mcgrail K^1
1 University of British Columbia, Vancouver, BC, Canada; ² Group Health Permanente, Seattle, WA, USA; ³ McGill University, Montreal, QC, Canada

PCV21

EFFECTIVENESS OF CLINICAL PATHWAYS FOR INPATIENT HEARTH FAILURE TREATMENT: RESULTS OF A MULTICENTER CONTROLLED TRIAL
Panella M¹, Marchisio S², Barbieri A², Demarchi ML^1
1 University of Eastern Piedmont, Novara, Italy; ² Saint Andrew Hospital, Vercelli, Italy

PCV22

HEALTH AND ECONOMIC BURDEN OF POOR MEDICATION ADHERENCE IN THE UNITED STATES
Thompson D¹, Wang Y², Sarocco P³, Neumann P⁴, Weinstein M^2
1 Innovus Research, Inc, Medford, MA, USA; ² Harvard School of Public Health & Innovus Research, Inc, Boston, MA, USA; ³ Sanofi-Aventis US Pharma, Bridgewater, NJ, USA; ⁴ Harvard University, Boston, MA, USA

PCV23

EVALUATING THE DIAGNOSTIC VALIDITY OF ADMINISTRATIVE CLAIMS DATA FOR COMMON CHRONIC DISEASES
Yu YF, Bullano M, Willey VJ
HealthCore, Inc, Wilmington, DE, USA

PCV24

WHAT IS THE RELEVANCE OF AGE GROUPS IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS? A COST - UTILITY ANALYSIS IN MEXICO
Mould Quevedo JF, Contreras I, Salinas - Escudero G, Garduño J
Social Security Mexican Institute, México D.F, México D.F, Mexico

PCV25

COST EFFECTIVENESS OF ATORVASTATIN (LIPITOR) AS SINGLE THERAPY AND DUAL THERAPY WITH EZETIMIBE (ZETIA)
Bui T, Harrison DL
University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

PCV26

COST-EFFECTIVENESS OF EZETIMIBE CO- ADMINISTRATION IN CHD PATIENTS NOT AT GOAL WITH CURRENT STATIN THERAPY IN HONG KONG
Lee VW¹, Chan WK², Alemao E³, Yin D³, Cook JR⁴, Lee BS⁵, Chong AC², Tomlinson B¹, Wong JC⁵, Lee KKC^1
1 The Chinese University of Hong Kong, Shatin, Hong Kong, China; ² United Christian Hospital, Kwun Tong, Hong Kong, China; ³ Merck & Co., Inc, Whitehouse Station, NJ, USA; ⁴ Merck & Co., Inc, Blue Bell, PA, USA; ⁵ Prince of Wales Hospital, Shatin, Hong Kong, China

PCV27

AN ECONOMIC ANALYSIS OF EZETIMIBE/SIMVASTATIN COMPARED TO USUAL CARE WITH STATIN MONOTHERAPY
Nag SS¹, Sajjan SG¹, Kamal Bahl S¹, Cook JR², Soffer J³, Rajagopal G², John A⁴, Heithoff K⁴, Markson LE¹, Alexander CM^1
1 Merck & Co., Inc, West Point, PA, USA; ² Merck & Co., Inc, Blue Bell, PA, USA; ³ Merck & Co., Inc, Upper Gwynedd, PA, USA; ⁴ Schering-Plough Pharmaceuticals, Kenilworth, NJ, USA

PCV28

COST- UTILITY ANALYSIS FOR STATINS IN MEXICO
Mould Quevedo JF, Contreras I, Nevarez A, García - Contreras F, Constantino - Casas P, Garduño J
Social Security Mexican Institute, México D.F, México D.F, Mexico

PCV29

PREDICTORS OF COMPLIANCE AND PERSISTENCE TO STATIN THERAPY AMONG TEXAS MEDICAID PATIENTS
Dastani H¹, Shepherd M¹, Sasane R^2
1 University of Texas at Austin, Austin, TX, USA; ² AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PCV30

COMPLIANCE WITH STATIN TREATMENT: THE EFFECT OF SWITCHING TO ANOTHER STATIN AFTER TREATMENT INITIATION
Thiebaud P¹, Nichol MB¹, Patel BV^2
1 University of Southern California, Los Angeles, CA, USA; ² MedImpact Healthcare Systems, Inc, San Diego, CA, USA

PCV31

DOES PLAN DESIGN AFFECT THERAPY ADHERENCE FOR CHRONIC CONDITIONS?
Matlin OS, Marks AS, Xiao Q
Caremark Inc, Northbrook, IL, USA

PCV32

EVALUATION OF FACTORS RELATED TO DIAGNOSIS OF HYPERLIPIDEMIA: THE ROLE OF DIRECT-TO-CONSUMER ADVERTISING EXPENDITURES, HEALTH INSURANCE COVERAGE, AGE AND GENDER
Nair R, Shepherd M, Barner J, Lawson K, Wilson J, Warner D
University of Texas, Austin, TX, USA

PCV33

MONITORING OF LIPID LEVELS AND ADVERSE EVENTS AMONG TEXAS MEDICAID PATIENTS ON STATIN THERAPY
Dastani H¹, Shepherd M¹, Sasane R^2
1 University of Texas, Austin, TX, USA; ² AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PCV34

EFFECT OF CO-PAYMENT ON THE INITIATION OF STATINS AFTER CORONARY HEART DISEASE HOSPITALIZATION
Ye X¹, St.Peter WL¹, Gross CR¹, Xuan J^2
1 University of Minnesota, Minneapolis, MN, USA; ² Pfizer, New York, NY, USA

PCV35

EFFECT OF CLINICAL PHARMACIST INTERVENTION ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) OUTCOMES IN AN AMBULATORY SETTING
Guy-Alfandary S, Lavi S, Raz M, Triki N
Maccabi Healthcare Services, Rishon Le Zion, Israel

PCV36

CHOLESTEROL GOAL ATTAINMENT IN DYSLIPIDEMIC TREATED PATIENTS AND INCIDENCE OF CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE
Van Ganse E¹, Souchet T², Laforest L³, Moulin P⁴, Bertrand M⁵, Le Jeunne P⁶, Chretin S³, De Pouvourville G^7
1 CHU Lyon, Pierre Bénite, France; ² Merck Sharp & Dohme - Chibret, Paris, France; ³ Pharmacoepidemiology, CHU-Lyon, Pierre Bénite, France; ⁴ Hopital Louis Pradel, Lyon, France; ⁵ CHU - Lille, Lambersart, France; ⁶ Thales, Boulogne Billancourt, France; ⁷ INSERM U 537, Le Kremlin-Bicêtre, France

PCV37

PREDICTING STATIN COMPLIANCE IN NEW STARTERS WITH PHARMACY CLAIMS
Thiebaud P¹, Nichol MB², Patel BV^3
1 University of Southern California, Los Angeles, CA, USA; ² University of Southern California, School of Pharmacy, Los Angeles, CA, USA; ³ MedImpact Healthcare Systems, Inc, San Diego, CA, USA

PCV38

A COMPARISON OF THE ELIXHAUSER AND CHARLSON INDICES TO CONTROL FOR CONFOUNDING IN HEALTH OUTCOMES STUDIES
Farley J
University of Minnesota, Minneapolis, MN, USA

PCV39

WITHDRAWN

PCV40

PHARMACOECONOMIC EVALUATION OF ANTIHYPERTENSIVE THERAPY IN OLABISI ONABANJO UNIVERSITY TEACHING HOSPITAL , SAGAMU, OGUN SATATE, NIGERIA
Suleiman IA¹, Lumor HA^2
1 University of Lagos, Lagos, Nigeria; ² Olabisi Onabanjo University Ago Iwoye, Sagamu Campus, Sagamu, Nigeria

PCV41

PATIENT EDUCATION AND ADHERENCE AND HYPERTENSION CONTROL IN TWO ACADEMIC MEDICAL CENTER PRIMARY CARE PRACTICES
Crawford A, Roco C, Riggio J, Valko G, Goldfarb N, Nash DB
Jefferson Medical College, Philadelphia, PA, USA

PCV42

ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS RELATED TO COPAYMENT LEVEL
Taira DA¹, Davis JW¹, Wong KS², Frech F², Chung RS^1
1 Hawaii Medical Service Association (BCBS of Hawaii), Honolulu, HI, USA; ² Novartis Pharmaceutical Corporation, East Hanover, NJ, USA

PCV43

INSURANCE COVERAGE AND AMBULATORY CARE OF HYPERTENSION FOR THE NEAR ELDERLY
Raofi S¹, Shinogle J^2
1 National Center for Health Statistics, Hyattsville, MD, USA; ² Centers for Disease Control and Prevention, Hyattsville, MD, USA

PCV44

PHYSICAL INACTIVITY IS ASSOCIATED WITH INCREASED HEALTH CARE USE AND EXPENDITURES IN INDIVIDUALS WITH HYPERTENSION
Iyer R, Modi A
University of Louisiana at Monroe, Monroe, LA, USA

PCV45

ANTIHYPERTENSIVE THERAPY AFTER ALLHAT: ARE MORE PATIENTS STARTING WITH DIURETICS?
Petrilla AA¹, Chapman RH¹, Lidsky L², Rucker M², Ollendorf DA², Benner JS^1
1 ValueMedics Research, LLC, Arlington, VA, USA; ² PharMetrics, Inc, Watertown, MA, USA

PCV46

USE OF NON-US SUPPLIED PHARMACEUTICALS IN THE TREATMENT OF HYPERTENSION IN A LATINO POPULATION IN LOS ANGELES COUNTY, CA, USA
Wang SM, Bonnet PO, Wu J, Johnson KA
University of Southern California, Los Angeles, CA, USA

PCV47

USE OF ANTIHYPERTENSIVE MEDICATIONS AMONG VETERANS NEWLY DIAGNOSED WITH HYPERTENSION
Vincze G¹, Barner J^2
1 Novartis Pharma AG, Basel, Switzerland; ² University of Texas, Austin, TX, USA

PCV48

ASSESSMENT OF THE VALIDITY OF TWO CLAIMS-BASED ALGORITHMS IN IDENTIFYING HYPERTENSIVE PATIENTS
Bullano M¹, Kamat S¹, Barlas S², Willey VJ¹, Makin C¹, Watson DJ², Brenneman SK^3
1 HealthCore, Inc, Wilmington, DE, USA; ² Merck Research Laboratories, Blue Bell, PA, USA; ³ Merck & Co., Inc, West Point, PA, USA

PCV49

ADVANTAGES AND LIMITATIONS OF USING A WEB-BASED SURVEY TO OBTAIN PATIENT-REPORTED OUTCOMES
Chen KS¹, Plauschinat CA², Frech F², Dubois RW¹, Doan Q^1
1 Cerner Health Insights, Beverly Hills, CA, USA; ² Novartis Pharmaceutical Corporation, East Hanover, NJ, USA

PCV50

VENOUS THROMBOEMBOLISM PROPHYLAXIS AND DRUG USE VALUE OF ENOXAPARIN IN HOSPITALIZED MYOCARDIAL INFARCTION PATIENTS
Balu S¹, Vogenberg FR², Lichtig L³, O'Connor P^3
1 Purdue University, West Lafayette, IN, USA; ² Aon Consulting Life Sciences Practice, Providence, RI, USA; ³ Aon Consulting Life Sciences Practice, Wellesley, MA, USA

PCV51

SHORT AND LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDROGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION: A CANADIAN ECONOMIC ANALYSIS
Kolm P¹, Veledar E¹, Forte L², Amin M³, Bouin O⁴, Jackson J⁵, Gabriel S⁴, Weintraub WS^1
1 Emory University, Atlanta, GA, USA; ² Sanofi-Synthelabo, Markham, ON, Canada; ³ Bristol-Myers Squibb, St Laurent, QC, Canada; ⁴ Sanofi-Aventis, Bagneux, France; ⁵ Bristol-Myers Squibb Company, Princeton, NJ, USA

PCV52

A MULTI-COUNTRY HEALTH ECONOMIC EVALUATION OF N-3 POLYUNSATURATED FATTY ACIDS (PUFA) IN THE SECONDARY PREVENTION AFTER MI
Lamotte M¹, Annemans L¹, Oelze R^2
1 IMS Health, Brussels, Brussels, Belgium; ² Solvay Pharmaceuticals, Hannover, Germany

PCV53

COST ANALYSIS ON ANTICOAGULANT DRUG MARKET
He J¹, Griffin B¹, Mahoney A¹, Young J², Burleigh E^1
1 Solucient, Berkeley Heights, NJ, USA; ² Solucient, Ann Arbor, MI, USA

PCV54

ECONOMIC AND HUMANISTIC BURDEN OF POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE IN GERMANY
Brüggenjürgen BH¹, Reinhold T¹, Lenz C², Mundhenke M², Willich SN^1
1 University of Berlin, Berlin, Germany; ² Pfizer Pharma GmbH, Karlsruhe, Germany

PCV55

PREVALENCE OF METABOLIC SYMDROME IN KOREAN AMERICANS IN THE UNITED STATES
Lee J¹, Chung YH¹, Mak M², Kim K², Wong SL^3
1 Korean American Physician Organization, New York, NY, USA; ² Oxford Health Plans, New York, NY, USA; ³ Pfizer Inc, Syosset, NY, USA

PCV56

EVALUATION AND COMPARISON OF DIFFERENT MODELS OF METABOLIC SYNDROME USING CONFIRMATORY FACTOR ANALYSIS
Shah S¹, Novak S¹, Shepherd M^2
1 University of Texas at Austin, Austin, TX, USA; ² University of Texas, Austin, TX, USA

PCV57

COST OF MAJOR BLEEDING FOLLOWING MAJOR ORTHOPEDIC SURGERY
Vera-Llonch M, Hagiwara M, Oster G
Policy Analysis, Inc (PAI), Brookline, MA, USA

PCV58

CLINICAL AND ECONOMIC ISSUES IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED ORTHOPEDIC PATIENTS: ENOXAPARIN VERSUS WARFARIN
Balu S¹, Vogenberg FR², Lichtig L², O'Connor P^2
1 Purdue University, West Lafayette, IN, USA; ² Aon Consulting Life Sciences Practice, Wellesley, MA, USA

PEN1

COST SAVINGS ASSOCIATED WITH FINER DOSING INCREMENTS THROUGH THE USE OF NORDITROPIN NORDIFLEX® IN THE UNITED STATES
Joshi AV¹, Gore T¹, Russell MW^2
1 Novo Nordisk Inc, Princeton, NJ, USA; ² Boston Health Economics, Inc, Waltham, MA, USA

PEN2

COST-UTILITY OF NORDITROPIN® (R-DNA SOMATROPIN) IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
Joshi AV¹, Nicklasson L¹, Russell MW^2
1 Novo Nordisk Inc, Princeton, NJ, USA; ² Boston Health Economics, Inc, Waltham, MA, USA

PEN3

HEALTH STATUS VALUES (UTILITIES) FOR THE SWEDISH POPULATION: A MODEL BASED ON THE EQ-5D ASSESSMENT OF ACTUAL HEALTH STATE, USING JACKKNIFE METHOD AND MULTIPLE REGRESSION ANALYSIS
Jonsson B¹, Koltowska-Haggstrom M², Isacson D³, Bingefors K(^3
1 Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden; ² Pfizer Health AB, Stockholm, Sweden; ³ Department of Pharmacy, Uppsala University, Uppsala, Sweden

PEN4

GENERIC AND DISEASE - SENSITIVE INSTRUMENTS SEEM TO MEASURE QUALITY OF LIFE IN A SIMILAR WAY: RESULTS OF THE EQ-5D AND QOL-AGHDA SURVEY IN THE SWEDISH POPULATION
Koltowska-Haggstrom M¹, Jonsson B², Isacson D³, Bingefors K(^3
1 Pfizer Health AB, Stockholm, Sweden; ² Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden; ³ Department of Pharmacy, Uppsala University, Uppsala, Sweden

PEN5

ESTIMATING THE QUALITY OF LIFE DEFICIT IN ADULT GROWTH HORMONE DEFICIENCY USING AN EQ-5D CALIBRATED INDEX
Kind P¹, Koltowska-Haggstrom M^2
1 University of York, York, United Kingdom; ² University of Uppsala, Uppsala, Sweden

PEN6

EVALUATION OF THE ASSOCIATION BETWEEN HEIGHT AND HEALTH-RELATED UTILITY (EQ5D_INDEX)
Woehl A¹, Davies S², Scanlon MF², Currie CJ^2
1 Kiel University, Kiel, Germany; ² Cardiff University School of Medicine, Cardiff, United Kingdom

PHM1

EFFECTIVENESS OF EPOETIN ALFA IN REDUCING THE NUMBER OF BLOOD TRANSFUSIONS IN CRITICALLY ILL SICU PATIENTS
Luh VW¹, Barlev A², Kern J^3
1 City of Hope National Medical Center, Duarte, CA, USA; ² Covance, San Diego, CA, USA; ³ University of Southern California, Los Angeles, CA, USA

PHM2

IMPACT OF ANEMIA ON IN-HOSPITAL FALLS: A MATCHED CASE-CONTROL STUDY
Mallik AV¹, Coley KC¹, Kirisci L¹, Painter L^2
1 University of Pittsburgh, Pittsburgh, PA, USA; ² University of Pittsburgh Medical Center, Pittsburgh, PA, USA

PHM3

DOES ANEMIA CONTRIBUTE TO LONGER LENGTH OF STAY IN PATIENTS WITH IN-HOSPITAL FALLS?
Mallik AV¹, Coley KC¹, Kirisci L¹, Painter L^2
1 University of Pittsburgh, Pittsburgh, PA, USA; ² University of Pittsburgh Medical Center, Pittsburgh, PA, USA

PHM4

COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN CHINA
Staginnus U¹, Russell S^2
1 Premor Associates, New York, NY, USA; ² Premor Associates, Madrid, Spain

PHM5

RECOMBINANT HUMAN FACTOR VII USE: AN EVALUATION OF PATIENT CHARACTERISTICS AND OUTCOMES FROM AN ELECTRONIC DATABASE OF ACADEMIC HEALTH CENTERS
Magnetti S, Oinonen M, Matuszewski K
University HealthSystem Consortium, Oak Brook, IL, USA

PHM6

A HIDDEN EPIDEMIC AMONG ACUTE CARE INPATIENTS: ECONOMIC AND CLINICAL IMPACTS OF ANEMIA IN SELECTED CHRONIC DISEASES
Wang PF, Saunders W, Gaylord B, Vardireddy N
Premier Health Informatics, Charlotte, NC, USA

PHP1

COST EFFECTIVENESS OF INTERVENTIONS TO IMPROVE ADHERENCE: WHAT IS THE QUALITY OF THE EVIDENCE?
Elliott RA¹, Barber N², Horne R^3
1 Harvard University, Boston, MA, USA; ² University of London, London, United Kingdom; ³ University of Brighton, Brighton, Sussex, United Kingdom

PHP2

THE MEDINET-PROJECT - A FEASIBILITY STUDY ON MEDICATION COMPLIANCE UNDER REAL LIFE CONDITIONS.
Sterz R¹, Lebmeier M², Simon U^3
1 Abbott GmbH & Co. KG, Ludwigshafen, Rhineland-Palati, Germany; ² Sheffield University, Sheffield, United Kingdom; ³ ES-Q-Lab, Lauf, Bavaria, Germany

PHP3

IMPACT OF INCREASED COPAYMENTS ON THE SWITCHING AND DISCONTINUATION RATES FOR NON FORMULARY MEDICATIONS
Nair KV¹, Valuck RJ^2
1 University of Colorado Health Sciences Center, Denver, CO, USA; ² University of Colorado, Denver, CO, USA

PHP4

IMPACT OF COST ON MEDICATION COMPLIANCE IN PATIENTS WITH DIFFERENT LEVELS OF PERCEIVED BENEFITS
Fuldeore M¹, Krueger KP², Lee K¹, Berger BA², Bertram C¹, Shannon D², Ekelund R^2
1 Walgreens Health Initiatives, Deerfield, IL, USA; ² Auburn University, Auburn, AL, USA

PHP5

TOOLS TO INCREASE THE APPROPRIATENESS OF ALBUMIN UTILIZATION IN AN ITALIAN COMMUNITY HOSPITAL
Panella M¹, Marchisio S², Barbieri A², Broglio E^3
1 University of Eastern Piedmont, Novara, Italy; ² Saint Andrew Hospital, Vercelli, Italy; ³ Saint Andrew's Hospital, Vercelli, Italy

PHP6

SUMMARIZING DRUG USE OVER TIME: THE DRUG-O-GRAM
Gause D, Plauschinat CA
Novartis Pharmaceuticals, East Hanover, NJ, USA

PHP7

PRESCRIPTION DRUG NONCOMPLIANCE AMONG TRICARE BENEFICIARIES AT MILITARY PHARMACIES
Esposito D¹, Schone E², Williams T³, CyBulski K¹, Stapulonis R¹, Clusen N², Nolan E^4
1 Mathematica Policy Research, Inc, Princeton, NJ, USA; ² Mathematica Policy Research, Inc, Washington, DC, USA; ³ TRICARE Management Authority, Falls Church, VA, USA; ⁴ US Navy Pharmacy Board, Falls Church, VA, USA

PHP8

EVALUATION OF A CLINICAL PHARMACOKINETIC MONITORING SYSTEM
Chan YY¹, Tsai CY¹, Tarn YH², Tseng HM^3
1 Chang Gung Memorial Hospital, Taoyuen Hsien, Taiwan; ² Taipei City Hospital, Taipei, Taipei, Taiwan; ³ Chang Gung University, Taoyuen Hsien, Taiwan

PHP9

EVALUATION OF A PLAN-PARTICIPANT MAILING PROGRAM TO ENCOURAGE USE OF MAIL-SERVICE PHARMACY AND FORMULARY DRUGS
Powers CA¹, Parsons O², Meyer CM¹, Marks AS^2
1 Caremark Inc, Hunt Valley, MD, USA; ² Caremark Inc, Northbrook, IL, USA

PHP10

UTILIZATION AND COSTS OF A 90-DAY RETAIL PROGRAM IN COMPARISON WITH 30-DAY RETAIL AND MAIL SERVICES
Lee K, Sun SX, Kleyn L, McMurray J, Zagorski B, Bertram C
Walgreens Health Initiatives, Deerfield, IL, USA

PHP11

IMPACT OF A 90-DAY RETAIL PROGRAM ON PRESCRIPTION DRUG EXPENDITURES
Sun SX, Lee K, Kleyn L, McMurray J, Fuldeore M, Bertram C
Walgreens Health Initiatives, Deerfield, IL, USA

PHP12

SOCIAL AND ECONOMIC FACTORS AFFECTING INTENTIONAL PRESCRIPTION DRUG NON-COMPLIANCE AMONG NOVA SCOTIA SENIORS
Okihiro NR, Davis N, MacRae H
Mount St. Vincent University, Halifax, NS, Canada

PHP13

TRENDS IN THE PREVALENCE OF INAPPROPRIATE PRESCRIBING AMONG ELDERLY MEDICARE BENEFICIARIES, 1992-2001
Mahmood M¹, Craig BM¹, Ko Y¹, Armstrong EP^2
1 University of Arizona, Tucson, AZ, USA; ² University of Arizona College of Pharmacy, Tucson, AZ, USA

PHP14

MAKING A CASE FOR EMPLOYING SOCIETAL PERSPECTIVE IN THE EVALUATION OF MEDICAID FORMULARIES
Roy S, Madhavan SS
West Virginia University, Morgantown, WV, USA

PHP15

PHARMACOECONOMIC EDUCATION AT MEDICAL SCHOOLS IN TURKEY
Tulunay F, Gulmez S, Ergun H
Ankara University School of Medicine, Ankara, Turkey

PHP16

ADVERTISING IN RESPONSE TO NEW PRODUCT ENTRY: AN EXAMINATION OF THE STRATEGIC ROLE OF PHARMACEUTICAL ADVERTISING ON MARKET COMPETITION
Kwong WJ¹, Norton EC^2
1 GlaxoSmithKline Research and Development, Research Triangle Park, NC, USA; ² The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PHP17

MODELING THE COST AND UTILIZATION OF MAIL ORDER VS. COMMUNITY PHARMACY IN A MEDICAID POPULATION
Valluri SC, Rodriguez-Monguio R, Seoane-Vazquez EC
Ohio State University, Columbus, OH, USA

PHP18

THE INFLUENCE OF DRUG COPAY CHANGE ON DRUG UTILIZATION: THE CASE OF SMALL-FIRM EMPLOYEES IN CALIFORNIA
Thiebaud P, Nichol MB
University of Southern California, Los Angeles, CA, USA

PHP19

MEDICATION NEEDS OF ELDERLY INDIVIDUALS WITHOUT PRESCRIPTION DRUG COVERAGE
Tran BV¹, Mullins CD², Shaya FT¹, McNally D¹, McEwan RN^3
1 University of Maryland, Baltimore, MD, USA; ² Pharmaceutical Health Services Research, Baltimore, MD, USA; ³ MEDBANK of Maryland, Inc, Towson, MD, USA

PHP20

EFFECT OF A PHARMACY BENEFIT CHANGE ON ACCURACY OF PRESCRIPTION DATABASE’S DAYS SUPPLY VARIABLE
Smith K¹, Smith D², Hazlet TK³, Malone DC^1
1 University of Arizona College of Pharmacy, Tucson, AZ, USA; ² Center for Health Research, Kaiser Permanente NW, Portland, OR, USA; ³ University of Washington, Seattle, WA, USA

PHP21

TRENDS IN PHARMACEUTICAL SPENDING GROWTH IN THE UNITED STATES, 1998-2002
Roberts WM, Rindress D
BioMedCom Consultants, inc, Montréal, QC, Canada

PHP22

IMPACT OF HEALTH INSURANCE ON HEALTH-RELATED QUALITY OF LIFE
Bharmal M, Thomas III J
Purdue University, West Lafayette, IN, USA

PHP23

WITHDRAWN

PHP24

THE DETERMINANTS OF EXPENDITURES ON PHARMACEUTICALS AND OTHER MEDICAL NON-DURABLES IN OECD COUNTRIES
Zhang D¹, Carlson A^2
1 University of Minnesota, Minneapolis, MN, USA; ² Data Intelligence, Eden Prairie, MN, USA

PHP25

ANALYSIS OF PRESCRIBING PATTERN WITH THE NEGATIVE LIST FORMULARY SYSTEM IN KOREA
Lee EK, Park EJ
Korea Institute for Health and Social Affairs, Seoul, SEOUL, South Korea

PHP26

THE CURRENT AND FUTURE OF PHARMACOECONOMICS IN UKRAINE
Zaliska OM, Parnovsky B
Lviv National Medical University named Danylo Galitsky, Lviv, Ukraine

PHP27

QUALITY OF ECONOMIC MODELS IN DOSSIERS SUBMITTED UNDER THE AMCP FORMAT
Colmenero F¹, Sullivan S², Watkins J³, Neumann P^4
1 Harvard School of Public Health, Boston, MA, USA; ² University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA; ³ Premera Blue Cross, Mountlake Terrace, WA, USA; ⁴ Harvard University, Boston, MA, USA

PHP28

THE EFFECT OF CORPORATE STRUCTURE ON FORMULARY DESIGN: THE CASE OF LARGE INSURANCE COMPANIES
Abrams L
Nu-Retail, Watsonville, CA, USA

PHP29

AN ANALYSIS OF PUBLICATION RATES OF ABSTRACTS PRESENTED AT THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH (ISPOR) INTERNATIONAL AND EUROPEAN CONFERENCES DURING YEARS 2000 THROUGH 2003
Vo PG¹, Nichol MB², Borok GM^3
1 University of Southern California, Los Angeles, CA, USA; ² University of Southern California, School of Pharmacy, Los Angeles, CA, USA; ³ AstraZeneca, Encino, CA, USA

PHP30

USE OF EMERGENCY DEPARTMENTS BY HOMELESS PERSONS FOR NON-EMERGENCY CARE DURING ONE YEAR: RESOURCE USE AND COST
O'Brien JA¹, Pitoniak-Morse C¹, Jacobs LM^2
1 Caro Research Institute, Concord, MA, USA; ² University of Connecticut Medical School, Farmington, CT, USA

PHP31

SAFETY NET ACTIVITIES STRUCTURAL CHARACTERISTICS & MEMBERSHIP IN LOCAL HOSPITAL SYSTEMS
Khan N
University of Illinois at Chicago, Chicago, IL, USA

PHP32

TRENDS AND OUTCOMES ASSOCIATE WITH DTCA PRINT SUMMARY FORMATS: A FOUR YEAR STUDY OF PRINT ADS
Sansgiry SS¹, Kawatkar AA¹, Chanda S¹, Jayawant S², Sail K^1
1 University of Houston, Houston, TX, USA; ² University of Houston College of Pharmacy, Houston, TX, USA

PHP33

UTILITY OF MEDIA ON HEALTH PROMOTION AND SELFMEDICATION
Tasic D¹, Mladenovska D², Tasic L^1
1 Faculty of Pharmacy, Belgrade University, Belgrade, Serbia and Montenegro; ² Public Health Center Vrsac, Vrsac, Serbia and Montenegro

PHP34

AN ASSESSMENT OF THE ASSOCIATION BETWEEN UNDERLYING WORKER MEDICAL CONDITIONS AND WORKER ABSENTEEISM IN THE US
Mavros P¹, Pietri G^2
1 Merck & Co., Inc, Whitehouse Station, NJ, USA; ² Rutgers University, Piscataway, NJ, USA

PHP35

OUTCOMES OF TECHNOLOGY APPLICATION ON PHARMACISTS JOB PERFORMANCE: THE ROLE OF PERSONAL DIGITAL ASSISTANTS
Sikri S, Sansgiry SS
University of Houston, Houston, TX, USA

PHP36

EXAMINING THE QUALITY OF HEALTH ECONOMIC ANALYSES SUBMITTED TO THE PHARMACEUTICAL BENEFITS BOARD IN SWEDEN. – DATA FROM THE FIRST TWO YEARS
Odeberg S, Engstrom A, Jacob J, Lundin D, Ramsberg J
Pharmaceutical Benefits Board, Solna, Sweden

PHP37

EVALUATING PHARMACEUTICALS FOR REIMBURSEMENT IN KOREA
Choi SE¹, Sullivan SD^2
1 Health Insurance Review Agency, Seoul, South Korea; ² University of Washington, Seattle, WA, USA

PHP38

A CENTRAL COMPUTERIZED DRUG PRIOR-AUTHORIZATION PROCESS IN A MANAGED CARE SETTING IN ISRAEL
Kahan NR, Blackman S, Brami JL, Waitman DA
Leumit Health Fund (HMO), Tel-Aviv, Israel

PHP39

DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A COMMERCIAL POPULATION
Cantrell CR¹, Martin BC^2
1 GlaxoSmithKline, Research Triangle Park, NC, USA; ² University of Arkansas for Medical Sciences, Little Rock, AR, USA

PHP40

DEVELOPING KEY PERFORMANCE INDICATORS FOR THE AUSTRALIAN REIMBURSEMENT SYSTEM
Abela M¹, Davey P¹, Carroll J¹, Brown B², Yates R^1
1 Medical Technology Assessment Group Pty Ltd, Sydney, NSW, Australia; ² Medical Technology Assessment Group Ltd, London, London, United Kingdom

PHP41

A PRELIMINARY ANALYSIS OF THE RELATIONSHIP BETWEEN CONSULTATION LENGTH AND PRESCRIBER ACTIVITY IN UK GENERAL PRACTICE
Richard LJ¹, Lister SP^2
1 Heron Evidence Development, Letchworth Garden City, United Kingdom; ² CompuFile Ltd, Woking, Surrey, United Kingdom

PHP42

AN EXPLORATION OF PATIENT FACTORS INFLUENCING PRESCRIBER ACTIVITY IN UK GENERAL PRACTICE
Richard LJ¹, Lister SP^2
1 Heron Evidence Development, Letchworth Garden City, United Kingdom; ² CompuFile Ltd, Woking, Surrey, United Kingdom

PHP43

FACTORS THAT INFLUENCE PRESCRIBING OF LOW-MOLECULAR-WEIGHT HEPARINS
Blackburn J¹, Walton SM¹, Nutescu EA¹, Park H¹, Schumock G¹, Lewis R², Finley JM^3
1 University of Illinois at Chicago, Chicago, IL, USA; ² ProCe Inc, Bartlett, IL, USA; ³ Broadlane, Dallas, TX, USA

PHP44

USING THE TRANSTHEORETICAL MODEL (TTM) TO EXPLAIN, PREDICT OR INFLUENCE PHYSICIAN PATIENT CARE BEHAVIOR: A SYSTEMATIC REVIEW
Roy AN, Kavookjian J
West Virginia University, Morgantown, WV, USA

PHP45

EVALUATING THE EFFECTIVENESS OF A PROTOCOL FOR SEDATION OF MECHANICALLY VENTILATED PATIENTS IN AN ACUTE CARE SETTING
Basskin LE
North Shore Medical Center, Cooper City, FL, USA

PHP46

IMPACT OF PRESCRIBING GUIDELINES FOR INPATIENT ANTICOAGULATION
Blackburn J¹, Schumock G¹, Nutescu EA¹, Walton SM¹, Finley JM², Lewis R^3
1 University of Illinois at Chicago, Chicago, IL, USA; ² Broadlane, Dallas, TX, USA; ³ ProCe Inc, Bartlett, IL, USA

PHP47

COST-MINIMIZATION ANALYSIS OF SEROLOGIC SCREENING POLICY OPTIONS FOR US ARMY ACCESSION IMMUNIZATIONS
Nevin RL¹, Niebuhr DW¹, Frick KD^2
1 Walter Reed Army Institute of Research, Silver Spring, MD, USA; ² Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PHP48

ISPOR PHARMACOECONOMICS & OUTCOMES RESEARCH ABSTRACTS: TRENDS & QUALITY INDICATORS
Dix Smith M¹, McGhan WF^2
1 ISPOR, Lawrenceville, NJ, USA; ² University of the Sciences, Philadelphia, PA, USA

PHP49

BRIEF SUMMARY FORMATS OF DTCA TO IMPROVE CONSUMER COMPREHENSION
Sansgiry SS, Kawatkar AA
University of Houston, Houston, TX, USA

PIH1

INCORPORATING OF HERD IMMUNITY INTO PHARMACOECONOMIC EVALUATION OF PNEUMOCOCCAL CONJUGATE VACCINE PNC-7
Claes C¹, Reinert RR², Schulenburg JM^1
1 University of Hanover, Hannover, Germany; ² Institute for Medical Microbiology, Aachen, Germany

PIH2

THE COST-EFFECTIVENESS OF EXPANDING NEWBORN SCREENING FOR INHERITED METABOLIC DISORDERS USING TANDEM MASS SPECTROMETRY
Cipriano LE, Rupar CA, Zaric GS
University of Western Ontario, London, ON, Canada

PIH3

DIRECT COST OF TREATMENT FOR AUTISM SPECTRUM DISORDER IN CALIFORNIA MEDICAID
Flanders S¹, Engelhart L^2
1 Janssen Medical Affairs, Grayslake, IL, USA; ² Janssen Medical Affairs, Titusville, NJ, USA

PIH4

THE QUALITY OF COMMUNITY PEDIATRICIAN'S PRESCRIPTIONS
Triki N, Cohen R, Raz M
Maccabi Healthcare Services, Rishon Le Zion, Israel

PIH5

USE OF ANTIBIOTICS IN ASSOCIATION WITH DIAGNOSES OF UPPER RESPIRATORY INFECTIONS IN A LARGE ISRAELI HMO
Silverman BG, Hemo B, Friedman N
Maccabi Healthcare Services, Tel Aviv, Israel

PIH6

TESTING FOR STREPTOCOCCAL INFECTIONS IN CHILDREN WITH PHARYNGITIS TREATED WITH ANTIBIOTICS IN A LARGE ISRAELI HMO, 2003
Silverman BG, Hemo B, Friedman N
Maccabi Healthcare Services, Tel Aviv, Israel

PIH7

THE PREVALENCE OF POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE ELDERLY
Jiang JZ¹, Fu AZ², Perri M^1
1 University of Georgia, Athens, GA, USA; ² University of North Carolina, Chapel Hill, NC, USA

PIH8

INAPPROPRIATE PRESCRIBING FOR ELDERLY PATIENTS IN TWO OUTPATIENT SETTINGS
Poston S, Liu-Chen X, Maio V, Hartmann CW, Arenson C, Diamond JJ
Jefferson Medical College, Philadelphia, PA, USA

PIH9

MORAL HAZARD AND PRESCRIPTION DRUG USE AMONG NON-INSTITUTIONALIZED ELDERLY MEDICARE BENEFICIARIES
Gajria KL¹, Pyles MA^2
1 QualityMetric Inc, Lincoln, RI, USA; ² Viginia Commonwealth University, Richmond, VA, USA

PIH10

AN EXAMINATION OF SELF-REPORTED CHRONIC CONDITIONS AND HEALTH STATUS IN THE 2001 MEDICARE HEALTH OUTCOMES SURVEY
Ko Y, Coons SJ
University of Arizona, Tucson, AZ, USA

PIH11

THE EFFECT OF OVER-THE-COUNTER DRUG MISUSE AND THE ASSOCIATED ADES ON HRQOL IN THE ELDERLY
Sansgiry SS, Nadkarni A, Chanda S
University of Houston, Houston, TX, USA

PIH12

RELATIONSHIP BETWEEN QUALITY OF LIFE AND INAPPROPRIATE DRUG USE: A RETROSPECTIVE ANALYSIS IN AN ELDERLY POPULATION
Jiang JZ, Franic D
University of Georgia, Athens, GA, USA

PIH13

COST-EFFECTIVENESS ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENTS
DiSantostefano R, Biddle A, Lavelle J
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PIH14

USE OF SILDENAFIL CITRATE IN NON-ADHERENT PATIENTS WITH CVD, DIABETES OR DEPRESSION
McLaughlin T¹, Harnett J², Scott B³, Burhani S^1
1 NDCHealth, Phoenix, AZ, USA; ² Pfizer Inc, New York, NY, USA; ³ NDCHealth, Westerville, OH, USA

PIH15

IMPACT OF BENEFIT DESIGN ON PDE-5 UTILIZATION AND COSTS IN A LARGE PBM DATABASE
Patel BV¹, Leslie RS¹, Harnett J², Szczotka A^1
1 MedImpact Healthcare Systems, Inc, San Diego, CA, USA; ² Pfizer Inc, New York, NY, USA

PIH16

UTILIZATION PATTERNS OF SIDENAFIL CITRATE IN A SENIOR MANAGED CARE POPULATION
Harnett J¹, Broderick WC^2
1 Pfizer Inc, New York, NY, USA; ² Ingenix, Houston, TX, USA

PIH17

EVALUATION OF TADALAFIL AND VARDENAFIL TREATMENT PATTERNS IN PRIOR SILDENAFIL USERS
Harnett J¹, McLaughlin T², Burhani S², Scott B^3
1 Pfizer Inc, New York, NY, USA; ² NDC Health, Phoenix, AZ, USA; ³ NDCHealth, Westerville, OH, USA

PIH18

DIRECT COSTS OF ERECTILE DYSFUNCTION IN A MANAGED CARE SETTING--EVIDENCE FROM A LARGE NATIONAL CLAIMS DATABASE
Sun P¹, Seftel A², Swindle R¹, Ye W¹, Pohl G^1
1 Lilly Research Laboratories, Indianapolis, IN, USA; ² Case Western University, School of Medicine, Cleveland, OH, USA

PIH19

COST-EFFECTIVENESS OF PHARMACIST PRESCRIBING AUTHORITY FOR EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA
Soon JA¹, Meckley LM², Levine M¹, Fielding D¹, Ensom MHH¹, Marciante KD^3
1 University of British Columbia, Vancouver, BC, Canada; ² University of Washington, Seattle, WA, USA; ³ Artis LLC, Tacoma, WA, USA

PIH20

COST OF ILLNESS STUDY OF NAUSEA AND VOMITING OF PREGNANCY IN CANADA
Piwko C¹, Ungar WJ¹, Einarson TR², Koren G^1
1 The Hospital for Sick Children, Toronto, ON, Canada; ² University of Toronto, Toronto, ON, Canada

PIH21

ADJUSTMENT FOR PUBLICATION BIAS CHANGES THE APPARENT EFFICACY OF HORMONE TREATMENT- UNADJUSTED DATA MIGHT DISTORT THE RISK –BENEFIT TRADE OFF
Badamgarav E¹, Borenstein J², Song PJ¹, Dubois RW^1
1 Cerner Health Insights, Beverly Hills, CA, USA; ² Cedars-Sinai Health System, Los Angeles, CA, USA

PIH22

NEW INSIGHTS INTO THE PLACEBO EFFECTS: A CASE STUDY OF THE EFFECTIVENESS OF HORMONE THERAPY ON THE FREQUENCY OF HOT FLASHES
Song PJ¹, Badamgarav E¹, Dubois RW¹, Borenstein J^2
1 Cerner Health Insights, Beverly Hills, CA, USA; ² Cedars-Sinai Health System, Los Angeles, CA, USA

PIH23

HEALTH PREFERENCES AND WILLINGNESS TO PAY TO REDUCE EXPOSURE TO POST-MENOPAUSAL RISK FACTORS